vs
Side-by-side financial comparison of Basel Medical Group Ltd (BMGL) and Oncology Institute, Inc. (TOI). Click either name above to swap in a different company.
Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
Revenue
BMGL
TOI
| Q4 25 | — | $142.0M | ||
| Q3 25 | — | $136.6M | ||
| Q2 25 | — | $119.8M | ||
| Q1 25 | — | $104.4M | ||
| Q4 24 | — | $100.3M | ||
| Q3 24 | — | $99.9M | ||
| Q2 24 | — | $98.6M | ||
| Q1 24 | — | $94.7M |
Net Profit
BMGL
TOI
| Q4 25 | — | $-7.5M | ||
| Q3 25 | — | $-16.5M | ||
| Q2 25 | — | $-17.0M | ||
| Q1 25 | — | $-19.6M | ||
| Q4 24 | — | $-13.2M | ||
| Q3 24 | — | $-16.1M | ||
| Q2 24 | — | $-15.5M | ||
| Q1 24 | — | $-19.9M |
Operating Margin
BMGL
TOI
| Q4 25 | — | -4.9% | ||
| Q3 25 | — | -5.9% | ||
| Q2 25 | — | -9.4% | ||
| Q1 25 | — | -9.5% | ||
| Q4 24 | — | -11.9% | ||
| Q3 24 | — | -13.9% | ||
| Q2 24 | — | -16.6% | ||
| Q1 24 | — | -19.0% |
Net Margin
BMGL
TOI
| Q4 25 | — | -5.3% | ||
| Q3 25 | — | -12.1% | ||
| Q2 25 | — | -14.2% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | -13.1% | ||
| Q3 24 | — | -16.1% | ||
| Q2 24 | — | -15.7% | ||
| Q1 24 | — | -21.0% |
EPS (diluted)
BMGL
TOI
| Q4 25 | — | $-0.04 | ||
| Q3 25 | — | $-0.14 | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | $-0.17 | ||
| Q1 24 | — | $-0.22 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.